scispace - formally typeset
M

Manon E. Wildenberg

Researcher at University of Amsterdam

Publications -  100
Citations -  10232

Manon E. Wildenberg is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Inflammatory bowel disease & Medicine. The author has an hindex of 27, co-authored 82 publications receiving 8152 citations. Previous affiliations of Manon E. Wildenberg include University of California, Los Angeles & Leiden University Medical Center.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)

Daniel J. Klionsky, +2983 more
- 08 Feb 2021 - 
TL;DR: In this article, the authors present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes.
Journal ArticleDOI

Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study

Marjolijn Duijvestein, +13 more
- 01 Dec 2010 - 
TL;DR: Administration of autologous bone marrow derived MSCs appears safe and feasible in the treatment of refractory Crohn's disease.
Journal ArticleDOI

Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis

Johannan F. Brandse, +9 more
- 01 Aug 2015 - 
TL;DR: High fecal concentrations of infliximab in the first days after therapy begins are associated with primary nonresponse, and additional studies are needed to determine how therapeutic antibodies are lost through the intestinal mucosa and how this process affects treatment response.
Journal ArticleDOI

Pretreatment with interferon-γ enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis.

Marjolijn Duijvestein, +15 more
- 01 Oct 2011 - 
TL;DR: It is demonstrated that IFN‐γ activation of MSCs increases their immunosuppresive capacities and importantly, their therapeutic efficacy in vivo, and prestimulation of MMSs with IFN-γ enhances their capacity to inhibit Th1 inflammatory responses, resulting in diminished mucosal damage in experimental colitis.